Spinal chemo shows promise in stopping brain spread of aggressive lymphoma
NCT ID NCT07493486
First seen Apr 09, 2026 · Last updated May 14, 2026 · Updated 4 times
Summary
This study tested a chemotherapy drug called thiotepa, given directly into the spinal fluid, to prevent a type of aggressive lymphoma (DLBCL) from spreading to the brain or spinal cord. It involved 31 high-risk adults and tracked how many developed brain involvement over two years. The goal was to see if this approach is safe and effective at preventing central nervous system relapse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Conditions
Explore the condition pages connected to this study.